205 related articles for article (PubMed ID: 36457063)
1. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia.
Bäumer N; Scheller A; Wittmann L; Faust A; Apel M; Nimmagadda SC; Geyer C; Grunert K; Kellmann N; Peipp M; Kailayangiri S; Gutierrez Suburu ME; Strassert CA; Schenk M; Greune L; Rüter C; Dersch P; Hartmann W; Rossig C; Neri D; Müller-Tidow C; Schwöppe C; Schliemann C; Khandanpour C; Lenz G; Berdel WE; Bäumer S
J Hematol Oncol; 2022 Dec; 15(1):171. PubMed ID: 36457063
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
3. Targeted siRNA nanocarrier: a platform technology for cancer treatment.
Bäumer N; Tiemann J; Scheller A; Meyer T; Wittmann L; Suburu MEG; Greune L; Peipp M; Kellmann N; Gumnior A; Brand C; Hartmann W; Rossig C; Müller-Tidow C; Neri D; Strassert CA; Rüter C; Dersch P; Lenz G; Koeffler HP; Berdel WE; Bäumer S
Oncogene; 2022 Apr; 41(15):2210-2224. PubMed ID: 35220407
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs).
Faust A; Bäumer N; Schlütermann A; Becht M; Greune L; Geyer C; Rüter C; Margeta R; Wittmann L; Dersch P; Lenz G; Berdel WE; Bäumer S
Angew Chem Int Ed Engl; 2022 Jan; 61(1):e202109769. PubMed ID: 34725904
[TBL] [Abstract][Full Text] [Related]
5. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
[TBL] [Abstract][Full Text] [Related]
6. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
[TBL] [Abstract][Full Text] [Related]
8. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
9. CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia.
Chen H; Jayasinghe MK; Yeo EYM; Wu Z; Pirisinu M; Usman WM; Pham TT; Lim KW; Tran NV; Leung AYH; Du X; Zhang Q; Phan AT; Le MTN
Cell Prolif; 2022 Sep; 55(9):e13255. PubMed ID: 35851970
[TBL] [Abstract][Full Text] [Related]
10. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
12. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
[TBL] [Abstract][Full Text] [Related]
13. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
14. De Novo design of a humanized antiCD33 antibody-oridonin conjugate for acute myeloid leukemia therapy.
Feng H; Liu Y; Zhang M; Liu R; Wang J; Wang W; He P; Zhang P; Niu F
Biochem Biophys Res Commun; 2022 Nov; 629():152-158. PubMed ID: 36122452
[TBL] [Abstract][Full Text] [Related]
15. miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.
Gamlen HA; Romer-Seibert JS; Lawler ME; Versace AM; Goetz ML; Feng Y; Guryanova OA; Palmisiano N; Meyer SE
Clin Cancer Res; 2022 Oct; 28(20):4574-4586. PubMed ID: 35943291
[TBL] [Abstract][Full Text] [Related]
16. RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with
Sidorova OA; Sayed S; Paszkowski-Rogacz M; Seifert M; Camgöz A; Roeder I; Bornhäuser M; Thiede C; Buchholz F
Cells; 2022 Mar; 11(5):. PubMed ID: 35269477
[No Abstract] [Full Text] [Related]
17. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
18. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
[TBL] [Abstract][Full Text] [Related]
19. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
[TBL] [Abstract][Full Text] [Related]
20. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
